Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Kidney function and psoriasis drug: a safety check

NCT ID NCT06380153

First seen Dec 29, 2025 · Last updated May 25, 2026 · Updated 21 times

Summary

This completed Phase 1 study tested how the psoriasis drug Hemay005 is processed in people with mild to moderate kidney impairment compared to those with normal kidneys. 26 adults took a single dose, and researchers measured drug levels in the blood to guide future dosing for patients with kidney problems. The study did not test if the drug works for psoriasis, only how the body handles it.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PSORIASIS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Union Hospital of Tongji Medical College; Huazhong University of Science and Technology

    Wuhan, Hubei, China

Conditions

Explore the condition pages connected to this study.